Of at least 24 biotech IPOs in 2012, 10 were completed in 4Q, raising $309.6 million. For the year, 24 deals raised $1.1 billion, compared with at least 19 that raised $972.7 million in 2011. The class of 2012 companies are up a median of 22%, led by the more than 2X increase in market value of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT). In December 2012, Intercept completed enrollment of 218 patients in the Phase III POISE trial of its lead compound